This site is intended for healthcare professionals
News

U.S commercial launch of the UroLift 2 system and UroLift ATC advanced tissue control system to manage benign prostatic hyperplasia.- Teleflex Inc.

Read time: 1 mins
Published:14th May 2022

The UroLift 2 System offers an improved workflow, including an ergonomic single trigger and an improved suture cutter in a reduced device and packaging footprint. The UroLift ATC System provides physicians with an enhanced delivery tip specifically designed to effectively treat patients with an obstructive median lobe.

Teleflex Incorporated announced the full U.S. commercial launch of its UroLift 2 System and UroLift ATC System, and that it will update the urology community through multiple in-booth presentations at the 2022 American Urological Association (AUA) annual meeting. The conference will take place in-person from May 13-16 in New Orleans.

About the UroLift System- The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 45 years or older (50 years outside U.S.). The UroLift permanent implants, delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction. Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. More than 300,000 men have been treated with the UroLift System in select markets worldwide.

Condition: Benign Prostatic Hyperplasia
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.